Stock Movers After FDA (FRX, MNKD, RDY, CYTX, RGEN)

Forest Laboratories Inc (NYSE:FRX) slipped to 0.28% to $31.79.
Bookmark and Share
Scottsdale, AZ ( January 24, 2011 - Forest Laboratories Inc (NYSE:FRX) slipped to 0.28% to $31.79. The Company along with Pierre Fabre Medicament announced preliminary top-line results from Phase III study of levomilnacipran for the treatment of major depressive disorder.

MannKind Corporation (NASDAQ:MNKD) is one of the top losers. The stock went down 42.92% to $5.20 after the Company failed to win approval from U.S. regulators to market its first product for diabetes called Afrezza.

Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY) declined 0.6% to $36.49. The Company has launched Pantoprazole Sodium Delayed-Released tablets in the US market. FDA approved Dr. Reddy's ANDA for Pantoprazole Sodium Delayed-Released tablets on January 19, 2011.

Cytori Therapeutics Inc (USA) (NASDAQ:CYTX) is down 2.71% to $5.39.The Company has received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE in the treatment of patients with acute heart attacks.

Repligen Corporation (NASDAQ:RGEN) soared 3.14% to $4.93 after the Company entered into an exclusive license agreement with the University of California for a patent application covering the use of histone deacetylase 3.Continue @

Our College stock website highlights penny stocks to buy as well as best stocks to invest in.


Tag Words: penny stock investing, penny stocks newsletters, penny stock investments
Categories: Investment

Press Release Contact
7161 E. Rancho Vista Dr.
Scottsdale, AZ 85251

Link To This Press Release:

Create Press Release
Press Release Options
About This Press Release
If you have any questions about this press release, please contact the listed publisher. Please do not contact prHWY as we cannot help you with your inquiry.